BRX011

About BioJiva

BioJiva is a private, clinical-stage biotech targeting the root cause of degenerative diseases through its novel platform of isotopically stabilized, oxidation-resistant PUFAs. The company's lead candidate, BRX011, is an orally administered, deuterated version of docosahexaenoic acid (DHA) being developed for geographic atrophy (GA) secondary to age-related macular degeneration, a leading cause of blindness with high unmet need. With a strong scientific foundation evidenced by extensive cited literature, BioJiva is positioned to address a key pathological driver in AMD and potentially other conditions linked to lipid peroxidation, though it faces the typical risks of an early-stage drug developer.

Therapeutic Areas